Cancer immunotherapy has emerged as a promising breakthrough in anti-cancer therapy, with the principle of activating the immune system to control and remove tumors. However, evaluating the efficacy of antibody drugs targeting human proteins on common mice can be challenging due to homologous immune checkpoint genes. Fortunately, Biocytogen offers high-quality and comprehensive humanized mouse models of immune checkpoints that aid in tumor immune drug research and development. Additionally, their powerful mouse model of human immune system reconstruction along with CDX and PDX models provide preclinical pharmacological efficacy study and drug safety evaluation for various types of tumor immunity and tumor drugs.

As living standards improve and dietary habits change, coupled with a fast-paced lifestyle and aging population, the incidence of metabolic diseases such as obesity, diabetes, and nonalcoholic steatohepatitis (NASH) is on the rise. This has become a major threat to human health and life expectancy, resulting in significant economic burden for patients and society at large. As such, it is a pressing public health issue worldwide. To address this challenge, scientists and pharmaceutical companies are exploring new opportunities to study the pathogenesis of metabolic diseases while developing more effective therapeutic drugs. Biocytogen offers various animal models of diabetes and NASH that can be combined with their series of heritable humanized mouse models for preclinical pharmacological efficacy studies as well as drug safety evaluations for various metabolic diseases.

The primary role of the human immune system is to safeguard the host against pathogenic infections that can cause harm to the body. However, in some cases, the immune system may develop an immune response to harmless substances, resulting in allergic diseases and autoimmune diseases (AID). Autoimmune diseases occur when the immune system fails to distinguish between "self" and "non-self," leading it to attack its own organs, tissues or cells. On the other hand, allergic diseases arise from tissue damage or dysfunction caused by repeated exposure of an antigen that has already triggered immunity. To support research on autoimmune and allergic diseases, Theosetta offers a range of robust animal models such as enteritis, rheumatoid arthritis, psoriasis, asthma and atopic dermatitis. These models are complemented by Biocytogen's series of heritable humanized mouse models for preclinical pharmacological efficacy studies and drug safety evaluations across various autoimmune and allergic conditions.